IOBT Mai-Britt Zocca buys $10K worth of shares
Dec 24, 2024, 5:33 AM
-5.24%
What does IOBT do
IO Biotech develops immune-modulating cancer therapies using its Twin technology platform, targeting tumor-induced immunosuppression. Its lead candidate, IO102-IO103, addresses key proteins IDO and PD-L1.
Mai-Britt Zocca bought 12,500 shares of IOBT on 23 December at $0.81 per share, worth a total of $10K. They now own 49,891 IOBT shares, or a 33% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.